AZD2171 : A highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer
- Author
- WEDGE, Stephen R1 ; KENDREW, Jane1 ; CHESTER, Rosemary1 ; JACKSON, Janet A1 ; BOFFEY, Sarah J1 ; KILBURN, Lyndsey L1 ; BARNETT, Sharon1 ; RICHMOND, Graham H. P3 ; WADSWORTH, Peter F3 ; WALKER, Mike4 ; BIGLEY, Alison L3 ; TAYLOR, Sian T1 ; HENNEQUIN, Laurent F2 ; COOPER, Lee1 ; BECK, Sarah1 ; JÜRGENSMEIER, Juliane M1 ; OGILVIE, Donald J1 ; VALENTINE, Paula J1 ; BARRY, Simon T1 ; BRAVE, Sandra R1 ; SMITH, Neil R1 ; JAMES, Neil H1 ; DUKES, Michael1 ; CURWEN, Jon O1
[1] Cancer Bioscience, AstraZeneca, Alderley Park, Macclesfield, Cheshire, United Kingdom
[2] AstraZeneca Pharma, Centre de Recherches, Z.I. La Pompelle, Chemin de Vrilly, Reims, France
[3] Safety Assessment, AstraZeneca, Alderley Park, Macclesfield, Cheshire, United Kingdom
[4] Discovery DMPK, AstraZeneca, Alderley Park, Macclesfield, Cheshire, United Kingdom - Source
Cancer research (Baltimore). 2005, Vol 65, Num 10, pp 4389-4400, 12 p ; ref : 67 ref
- CODEN
- CNREA8
- ISSN
- 0008-5472
- Scientific domain
- Medical oncology; Pharmacology drugs
- Publisher
- American Association for Cancer Research, Philadelphia, PA
- Publication country
- United States
- Document type
- Article
- Language
- English
- Keyword (fr)
- Inhibiteur enzyme Protein-tyrosine kinase Traitement Tumeur maligne Voie orale Récepteur VEGFR2 Enzyme Transferases
- Keyword (en)
- Enzyme inhibitor Protein-tyrosine kinase Treatment Malignant tumor Oral administration Vascular endothelial growth factor receptor 2 Enzyme Transferases
- Keyword (es)
- Inhibidor enzima Protein-tyrosine kinase Tratamiento Tumor maligno Vía oral Enzima Transferases
- Classification
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B02 Pharmacology. Drug treatments / 002B02R Antineoplastic agents
- Discipline
- Pharmacological treatments Tumours
- Origin
- Inist-CNRS
- Database
- PASCAL
- INIST identifier
- 16780352
Sauf mention contraire ci-dessus, le contenu de cette notice bibliographique peut être utilisé dans le cadre d’une licence CC BY 4.0 Inist-CNRS / Unless otherwise stated above, the content of this bibliographic record may be used under a CC BY 4.0 licence by Inist-CNRS / A menos que se haya señalado antes, el contenido de este registro bibliográfico puede ser utilizado al amparo de una licencia CC BY 4.0 Inist-CNRS
Access to the document
Install on your browser
DOI
10.1158/0008-5472.CAN-04-4409 
https://dx.doi.org/10.1158/0008-5472.CAN-04-4409
"O:13:\"PanistOpenUrl\":36:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000idc\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:29:\"10.1158\/0008-5472.CAN-04-4409\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:147:\"AZD2171 : A highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer\";s:9:\"\u0000*\u0000jtitle\";s:27:\"Cancer research (Baltimore)\";s:9:\"\u0000*\u0000stitle\";s:23:\"Cancer res. (Baltimore)\";s:7:\"\u0000*\u0000date\";s:4:\"2005\";s:9:\"\u0000*\u0000volume\";s:2:\"65\";s:8:\"\u0000*\u0000issue\";s:2:\"10\";s:8:\"\u0000*\u0000spage\";s:4:\"4389\";s:8:\"\u0000*\u0000epage\";s:4:\"4400\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0008-5472\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:5:\"WEDGE\";s:10:\"\u0000*\u0000aufirst\";s:9:\"Stephen R\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:23:{i:0;s:13:\"KENDREW, Jane\";i:1;s:17:\"CHESTER, Rosemary\";i:2;s:16:\"JACKSON, Janet A\";i:3;s:15:\"BOFFEY, Sarah J\";i:4;s:18:\"KILBURN, Lyndsey L\";i:5;s:15:\"BARNETT, Sharon\";i:6;s:21:\"RICHMOND, Graham H. P\";i:7;s:18:\"WADSWORTH, Peter F\";i:8;s:12:\"WALKER, Mike\";i:9;s:16:\"BIGLEY, Alison L\";i:10;s:14:\"TAYLOR, Sian T\";i:11;s:20:\"HENNEQUIN, Laurent F\";i:12;s:11:\"COOPER, Lee\";i:13;s:11:\"BECK, Sarah\";i:14;s:24:\"J\u00dcRGENSMEIER, Juliane M\";i:15;s:17:\"OGILVIE, Donald J\";i:16;s:18:\"VALENTINE, Paula J\";i:17;s:14:\"BARRY, Simon T\";i:18;s:15:\"BRAVE, Sandra R\";i:19;s:13:\"SMITH, Neil R\";i:20;s:13:\"JAMES, Neil H\";i:21;s:14:\"DUKES, Michael\";i:22;s:13:\"CURWEN, Jon O\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"CNREA8\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:147:\"AZD2171 : A highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer\";s:8:\"\u0000*\u0000place\";s:16:\"Philadelphia, PA\";s:6:\"\u0000*\u0000pub\";s:40:\"American Association for Cancer Research\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"12\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Panist access
"O:12:\"IstexOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:29:\"10.1158\/0008-5472.CAN-04-4409\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:147:\"AZD2171 : A highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer\";s:9:\"\u0000*\u0000jtitle\";s:27:\"Cancer research (Baltimore)\";s:9:\"\u0000*\u0000stitle\";s:23:\"Cancer res. (Baltimore)\";s:7:\"\u0000*\u0000date\";s:4:\"2005\";s:9:\"\u0000*\u0000volume\";s:2:\"65\";s:8:\"\u0000*\u0000issue\";s:2:\"10\";s:8:\"\u0000*\u0000spage\";s:4:\"4389\";s:8:\"\u0000*\u0000epage\";s:4:\"4400\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0008-5472\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:5:\"WEDGE\";s:10:\"\u0000*\u0000aufirst\";s:9:\"Stephen R\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:23:{i:0;s:13:\"KENDREW, Jane\";i:1;s:17:\"CHESTER, Rosemary\";i:2;s:16:\"JACKSON, Janet A\";i:3;s:15:\"BOFFEY, Sarah J\";i:4;s:18:\"KILBURN, Lyndsey L\";i:5;s:15:\"BARNETT, Sharon\";i:6;s:21:\"RICHMOND, Graham H. P\";i:7;s:18:\"WADSWORTH, Peter F\";i:8;s:12:\"WALKER, Mike\";i:9;s:16:\"BIGLEY, Alison L\";i:10;s:14:\"TAYLOR, Sian T\";i:11;s:20:\"HENNEQUIN, Laurent F\";i:12;s:11:\"COOPER, Lee\";i:13;s:11:\"BECK, Sarah\";i:14;s:24:\"J\u00dcRGENSMEIER, Juliane M\";i:15;s:17:\"OGILVIE, Donald J\";i:16;s:18:\"VALENTINE, Paula J\";i:17;s:14:\"BARRY, Simon T\";i:18;s:15:\"BRAVE, Sandra R\";i:19;s:13:\"SMITH, Neil R\";i:20;s:13:\"JAMES, Neil H\";i:21;s:14:\"DUKES, Michael\";i:22;s:13:\"CURWEN, Jon O\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"CNREA8\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:147:\"AZD2171 : A highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer\";s:8:\"\u0000*\u0000place\";s:16:\"Philadelphia, PA\";s:6:\"\u0000*\u0000pub\";s:40:\"American Association for Cancer Research\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"12\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Istex access
"O:16:\"UnpaywallOpenUrl\":35:{s:8:\"\u0000*\u0000email\";s:27:\"assistance-portail@inist.fr\";s:6:\"\u0000*\u0000fmt\";N;s:6:\"\u0000*\u0000doi\";s:29:\"10.1158\/0008-5472.CAN-04-4409\";s:6:\"\u0000*\u0000pii\";N;s:7:\"\u0000*\u0000pmid\";N;s:9:\"\u0000*\u0000atitle\";N;s:9:\"\u0000*\u0000jtitle\";N;s:9:\"\u0000*\u0000stitle\";N;s:7:\"\u0000*\u0000date\";N;s:9:\"\u0000*\u0000volume\";N;s:8:\"\u0000*\u0000issue\";N;s:8:\"\u0000*\u0000spage\";N;s:8:\"\u0000*\u0000epage\";N;s:8:\"\u0000*\u0000pages\";N;s:7:\"\u0000*\u0000issn\";N;s:8:\"\u0000*\u0000eissn\";N;s:9:\"\u0000*\u0000aulast\";N;s:10:\"\u0000*\u0000aufirst\";N;s:9:\"\u0000*\u0000auinit\";N;s:10:\"\u0000*\u0000auinitm\";N;s:5:\"\u0000*\u0000au\";N;s:9:\"\u0000*\u0000aucorp\";N;s:7:\"\u0000*\u0000isbn\";N;s:8:\"\u0000*\u0000coden\";N;s:8:\"\u0000*\u0000genre\";N;s:7:\"\u0000*\u0000part\";N;s:9:\"\u0000*\u0000btitle\";N;s:8:\"\u0000*\u0000title\";N;s:8:\"\u0000*\u0000place\";N;s:6:\"\u0000*\u0000pub\";N;s:10:\"\u0000*\u0000edition\";N;s:9:\"\u0000*\u0000tpages\";N;s:9:\"\u0000*\u0000series\";N;s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";N;}"
Unpaywall access
"O:16:\"EuropePMCOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:29:\"10.1158\/0008-5472.CAN-04-4409\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:147:\"AZD2171 : A highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer\";s:9:\"\u0000*\u0000jtitle\";s:27:\"Cancer research (Baltimore)\";s:9:\"\u0000*\u0000stitle\";s:23:\"Cancer res. (Baltimore)\";s:7:\"\u0000*\u0000date\";s:4:\"2005\";s:9:\"\u0000*\u0000volume\";s:2:\"65\";s:8:\"\u0000*\u0000issue\";s:2:\"10\";s:8:\"\u0000*\u0000spage\";s:4:\"4389\";s:8:\"\u0000*\u0000epage\";s:4:\"4400\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0008-5472\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:5:\"WEDGE\";s:10:\"\u0000*\u0000aufirst\";s:9:\"Stephen R\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:23:{i:0;s:13:\"KENDREW, Jane\";i:1;s:17:\"CHESTER, Rosemary\";i:2;s:16:\"JACKSON, Janet A\";i:3;s:15:\"BOFFEY, Sarah J\";i:4;s:18:\"KILBURN, Lyndsey L\";i:5;s:15:\"BARNETT, Sharon\";i:6;s:21:\"RICHMOND, Graham H. P\";i:7;s:18:\"WADSWORTH, Peter F\";i:8;s:12:\"WALKER, Mike\";i:9;s:16:\"BIGLEY, Alison L\";i:10;s:14:\"TAYLOR, Sian T\";i:11;s:20:\"HENNEQUIN, Laurent F\";i:12;s:11:\"COOPER, Lee\";i:13;s:11:\"BECK, Sarah\";i:14;s:24:\"J\u00dcRGENSMEIER, Juliane M\";i:15;s:17:\"OGILVIE, Donald J\";i:16;s:18:\"VALENTINE, Paula J\";i:17;s:14:\"BARRY, Simon T\";i:18;s:15:\"BRAVE, Sandra R\";i:19;s:13:\"SMITH, Neil R\";i:20;s:13:\"JAMES, Neil H\";i:21;s:14:\"DUKES, Michael\";i:22;s:13:\"CURWEN, Jon O\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"CNREA8\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:147:\"AZD2171 : A highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer\";s:8:\"\u0000*\u0000place\";s:16:\"Philadelphia, PA\";s:6:\"\u0000*\u0000pub\";s:40:\"American Association for Cancer Research\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"12\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Europe PubMed Central access
"O:11:\"BaseOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:29:\"10.1158\/0008-5472.CAN-04-4409\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:147:\"AZD2171 : A highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer\";s:9:\"\u0000*\u0000jtitle\";s:27:\"Cancer research (Baltimore)\";s:9:\"\u0000*\u0000stitle\";s:23:\"Cancer res. (Baltimore)\";s:7:\"\u0000*\u0000date\";s:4:\"2005\";s:9:\"\u0000*\u0000volume\";s:2:\"65\";s:8:\"\u0000*\u0000issue\";s:2:\"10\";s:8:\"\u0000*\u0000spage\";s:4:\"4389\";s:8:\"\u0000*\u0000epage\";s:4:\"4400\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0008-5472\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:5:\"WEDGE\";s:10:\"\u0000*\u0000aufirst\";s:9:\"Stephen R\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:23:{i:0;s:13:\"KENDREW, Jane\";i:1;s:17:\"CHESTER, Rosemary\";i:2;s:16:\"JACKSON, Janet A\";i:3;s:15:\"BOFFEY, Sarah J\";i:4;s:18:\"KILBURN, Lyndsey L\";i:5;s:15:\"BARNETT, Sharon\";i:6;s:21:\"RICHMOND, Graham H. P\";i:7;s:18:\"WADSWORTH, Peter F\";i:8;s:12:\"WALKER, Mike\";i:9;s:16:\"BIGLEY, Alison L\";i:10;s:14:\"TAYLOR, Sian T\";i:11;s:20:\"HENNEQUIN, Laurent F\";i:12;s:11:\"COOPER, Lee\";i:13;s:11:\"BECK, Sarah\";i:14;s:24:\"J\u00dcRGENSMEIER, Juliane M\";i:15;s:17:\"OGILVIE, Donald J\";i:16;s:18:\"VALENTINE, Paula J\";i:17;s:14:\"BARRY, Simon T\";i:18;s:15:\"BRAVE, Sandra R\";i:19;s:13:\"SMITH, Neil R\";i:20;s:13:\"JAMES, Neil H\";i:21;s:14:\"DUKES, Michael\";i:22;s:13:\"CURWEN, Jon O\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"CNREA8\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:147:\"AZD2171 : A highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer\";s:8:\"\u0000*\u0000place\";s:16:\"Philadelphia, PA\";s:6:\"\u0000*\u0000pub\";s:40:\"American Association for Cancer Research\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"12\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Base Search access
"O:12:\"ArXivOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:29:\"10.1158\/0008-5472.CAN-04-4409\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:147:\"AZD2171 : A highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer\";s:9:\"\u0000*\u0000jtitle\";s:27:\"Cancer research (Baltimore)\";s:9:\"\u0000*\u0000stitle\";s:23:\"Cancer res. (Baltimore)\";s:7:\"\u0000*\u0000date\";s:4:\"2005\";s:9:\"\u0000*\u0000volume\";s:2:\"65\";s:8:\"\u0000*\u0000issue\";s:2:\"10\";s:8:\"\u0000*\u0000spage\";s:4:\"4389\";s:8:\"\u0000*\u0000epage\";s:4:\"4400\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0008-5472\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:5:\"WEDGE\";s:10:\"\u0000*\u0000aufirst\";s:9:\"Stephen R\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:23:{i:0;s:13:\"KENDREW, Jane\";i:1;s:17:\"CHESTER, Rosemary\";i:2;s:16:\"JACKSON, Janet A\";i:3;s:15:\"BOFFEY, Sarah J\";i:4;s:18:\"KILBURN, Lyndsey L\";i:5;s:15:\"BARNETT, Sharon\";i:6;s:21:\"RICHMOND, Graham H. P\";i:7;s:18:\"WADSWORTH, Peter F\";i:8;s:12:\"WALKER, Mike\";i:9;s:16:\"BIGLEY, Alison L\";i:10;s:14:\"TAYLOR, Sian T\";i:11;s:20:\"HENNEQUIN, Laurent F\";i:12;s:11:\"COOPER, Lee\";i:13;s:11:\"BECK, Sarah\";i:14;s:24:\"J\u00dcRGENSMEIER, Juliane M\";i:15;s:17:\"OGILVIE, Donald J\";i:16;s:18:\"VALENTINE, Paula J\";i:17;s:14:\"BARRY, Simon T\";i:18;s:15:\"BRAVE, Sandra R\";i:19;s:13:\"SMITH, Neil R\";i:20;s:13:\"JAMES, Neil H\";i:21;s:14:\"DUKES, Michael\";i:22;s:13:\"CURWEN, Jon O\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"CNREA8\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:147:\"AZD2171 : A highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer\";s:8:\"\u0000*\u0000place\";s:16:\"Philadelphia, PA\";s:6:\"\u0000*\u0000pub\";s:40:\"American Association for Cancer Research\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"12\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
arXiv access
